Signet-ring cell/histiocytoid carcinoma of the axilla: a clinicopathological and genetic analysis of 11 cases, review of the literature, and comparison with potentially related tumours.
PIK3CA
apocrine
apocrine carcinoma
signet-ring cell/histiocytoid carcinoma
skin
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
revised:
15
06
2021
received:
14
05
2021
accepted:
19
06
2021
pubmed:
23
6
2021
medline:
1
3
2022
entrez:
22
6
2021
Statut:
ppublish
Résumé
The aim of this study was to determine the clinicopathological and genetic characteristics of axillary signet-ring cell/histiocytoid carcinoma (SRCHC) and the relationship between axillary SRCHC, eyelid SRCHC, and conventional apocrine carcinoma (AC). Eleven cases of axillary SRCHC, four cases of eyelid SRCHC, eight cases of axillary AC and five cases of invasive lobular carcinoma (ILC) were retrieved. Additionally, 14 axillary and 43 eyelid SRCHC cases from the literature were reviewed. Male predominance was prominent for axillary SRCHC (24:1) and eyelid SRCHC (42:5). Axillary SRCHC formed a circumscribed plaque or nodule, unlike eyelid SRCHC. Lymph node metastasis was predominantly seen in axillary SRCHC cases (72%, 18/25), but not in eyelid SRCHC cases (19%, 9/47). Axillary SRCHC and eyelid SRCHC were histopathologically similar and showed rare tubular formations. Immunoexpression of cytokeratin 7, cytokeratin 19, mucin 1, mucin 5AC, BerEP4 and androgen receptor was seen in all tested cases of the four diseases. Oestrogen and progesterone receptors were negative in both types of SRCHC and AC, but were strongly positive in ILCs. Complete loss of E-cadherin expression was seen in approximately one-quarter of both types of SRCHC and in all ILCs. PIK3CA mutations were detected in all three sequenced cases (two axillary SRCHCs and one eyelid SRCHC). The histopathological, immunohistochemical and genetic findings suggest that both types of SRCHC are phenotypic variants of AC, although there are differences in sex, macroscopic findings and the frequency of lymph node metastasis among the three. In contrast, ILC differs from the other three tumour types.
Types de publication
Comparative Study
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
926-939Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Kazakov DV, Brenn T, Kutzner H, Requena L, Sangueza OP. Signet-ring cell/histiocytoid carcinoma. In Elder DE, Massi D, Scolyer RA, Willemze R eds. World Health Organization classification of skin tumours. Lyon: IARC Press, 2018; 182.
Iwaya M, Uehara T, Yoshizawa A et al. A case of primary signet-ring cell/histiocytoid carcinoma of the eyelid: immunohistochemical comparison with the normal sweat gland and review of the literature. Am. J. Dermatopathol. 2012; 34; e139-e145.
Requena L, Prieto VG, Requena C et al. Primary signet-ring cell/histiocytoid carcinoma of the eyelid: a clinicopathologic study of 5 cases and review of the literature. Am. J. Surg. Pathol. 2011; 35; 378-391.
Ito Y, Ishida M, Ohe C, Miyasaka C, Tsuta K. Signet-ring cell/histiocytoid carcinoma in the axilla: a case report with genetic analysis using next-generation sequencing. J. Cutan. Pathol. 2020; 48; 102-105.
Raghavan SS, Clark M, Louie CY et al. Molecular profiling of a primary cutaneous signet-ring cell/histiocytoid carcinoma of the eyelid. J. Cutan. Pathol. 2020; 47; 860-864.
Cameselle-Teijeiro J, Alfonsín-Barreiro N, Allegue F, Caeiro M. Apocrine carcinoma with signet-ring cells and histiocytoid features: a potentially confusing axillary tumor. Pathol. Res. Pract. 1997; 193; 713-720.
Kuno Y, Numata T, Kanzaki T. Adenocarcinoma with signet ring cells of the axilla showing apocrine features: a case report. Am. J. Dermatopathol. 1999; 21; 37-41.
Wolff AC, Hammond ME, Allison KH et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. J. Clin. Oncol. 2018; 36; 2105-2122.
Karczewski KJ, Francioli LC, Tiao G et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 2020; 581; 434-443.
Auton A, Brooks LD, Durbin RM et al. A global reference for human genetic variation. Nature 2015; 526; 68-74.
Tadaka S, Saigusa D, Motoike IN et al. jMorp: Japanese multi omics reference panel. Nucleic Acids Res. 2018; 46; D551-D557.
Higasa K, Miyake N, Yoshimura J et al. Human genetic variation database, a reference database of genetic variations in the Japanese population. J. Hum. Genet. 2016; 61; 547-553.
Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010; 38; e164.
Pai RR, Kini JR, Achar C, Rau A, Kini H. Apocrine (cutaneous) sweat gland carcinoma of axilla with signet ring cells: a diagnostic dilemma on fine-needle aspiration cytology. Diagn. Cytopathol. 2008; 36; 739-741.
Misago N, Shinoda Y, Okawa T et al. Histiocytoid and signet-ring cell carcinoma of the axilla: a type of cutaneous apocrine carcinoma equivalent to histiocytoid lobular carcinoma of the breast. Clin. Exp. Dermatol. 2011; 36; 874-877.
Miyake T, Yamasaki O, Sugiu M et al. Primary signet-ring cell/histiocytoid carcinoma of the axilla expressing human epidermal growth factor receptor 2. J. Dermatol. 2012; 39; 1038-1040.
Droubi D, Zeitouni NC, Skitzki J, Bogner PN. Primary signet ring-cell carcinoma of the axilla. J. Cutan. Pathol. 2013; 40; 269-273.
Ishida M, Okabe H. Primary signet-ring cell/histiocytoid carcinoma of the axilla. Pathol. Int. 2013; 63; 374-376.
Berdugo J, Dumont-Mackay V, Brissy-Lachery S et al. Cutaneous apocrine carcinoma with an in situ component and histiocytoid and signet-ring cells. Am. J. Dermatopathol. 2017; 39; e76-e78.
Philips R, Langston L, Hwang H, Vandergriff T, Trynosky T, Berlingeri-Ramos AC. Primary cutaneous histiocytoid carcinoma with distant metastasis. J. Cutan. Pathol. 2017; 44; 376-380.
Rosen Y, Byunghoon K, Yermakov VA. Eccrine sweat gland tumor of clear cell origin involving the eyelids. Cancer 1975; 36; 1034-1041.
Grizzard WS, Torezynski E, Edwards WC. Adenocarcinoma of the eccrine sweat glands. Arch. Ophthalmol. 1976; 94; 2119-2123.
Kiyohara T, Kumakiri M, Kouraba S, Tokuriki A, Ansai S. Primary cutaneous signet ring cell carcinoma expressing cytokeratin 20 immunoreactivity. J. Am. Acad. Dermatol. 2006; 54; 532-536.
Thomas JW, Fu YS, Levine MR. Primary mucinous sweat gland carcinoma of the eyelid simulating metastatic carcinoma. Am. J. Ophthalmol. 1979; 87; 29-33.
Jakobiec FA, Austin P, Iwamoto T, Trokel SL, Marquardt MD, Harrison W. Primary infiltrating signet ring carcinoma of the eyelid. Ophthalmology 1983; 90; 291-299.
Bellman B, Gregory NA, Silvers D, Fountain KS. Sweat gland carcinoma with metastases to the skin: response to 5-fluorouracil chemotherapy. Cutis 1995; 55; 221-224.
Wollensak G, Witschel H, Böhm N. Signet ring cell carcinoma of the eccrine sweat glands in the eyelid. Ophthalmology 1996; 103; 1788-1793.
Kiyohara T, Kumakiri M, Anbo M, Ohkawara A, Minakawa H, Yoshida T. A case of signet ring cell carcinoma of the eyelids. Skin Cancer 1996; 11; 210-216.
Auw-Haedrich C, Böhm N, Weissenberger C. Signet ring cell carcinoma of the eccrine sweat gland in the eyelid, treated by radiotherapy alone. Br. J. Ophthalmol. 2000; 85; 112-113.
Gonzalo BE, Morcuende LJ, Montero MJC, Cuesta Gil M, De Castro F, Pombo J. Eccrine sweat glands carcinoma of the eyelid. Arch. Soc. Esp. Oftalmol. 2001; 76; 739-742.
González-Lois C, Rodriguez Peralto JL, Serrano Pardo R, Martínez-González MA, López-Ríos F. Cutaneous signet ring cell carcinoma: a report of a case and review of the literature. Am. J. Dermatopathol. 2001; 23; 325-328.
Langel DJ, Yeatts RP, White WL. Primary signet ring cell carcinoma of the eyelid: report of a case demonstrating further analogy to lobular carcinoma of the breast with a literature review. Am. J. Dermatopathol. 2001; 23; 444-449.
Kramer TR, Grossniklaus HE, McLean IW et al. Histiocytoid variant of eccrine sweat gland carcinoma of the eyelid and orbit. Ophthalmology 2002; 109; 553-559.
Betis F, Hofman V, Lagier J, Gastaud P, Santini J, Hofman P. Primary signet ring cell carcinoma of the eccrine sweat gland in the eyelid. Immunohistochemical and ultrastructural study of a case. J. Fr. Ophthalmol. 2002; 25; 547-551.
Swinson B, Ryan F, Barrett AW et al. Histiocytoid eccrine sweat gland carcinoma of the eyelid: report of a case. Clin. Exp. Dermatol. 2006; 31; 786-789.
Mortensen AL, Heegaard S, Clemmensen O, Prause JU. Signet ring cell carcinoma of the eyelid: the monocle tumour. APMIS 2008; 116; 326-332.
Kim YM, Kim JW, Oh DE. A case of histiocytoid variant eccrine sweat gland carcinoma of the orbit. Korean J. Ophthalmol. 2011; 25; 54-56.
Khoramnia R, Mayer C, Glaser E, Weirich G. Primary signet ring cell carcinoma of the eyelid in a young woman. Eye 2011; 25; 1380-1382.
Tomasini C. Primary ‘histiocytoid’ carcinoma of the eyelid. Eur. J. Dermatol. 2012; 22; 684-685.
Nazareth MR, Bogner P, Mansour N, Raghu PR, Mansour TN, Zeitouni NC. Primary adenocarcinoma of the eyelid with signet ring cell and histiocytoid features. Dermatol. Surg. 2012; 38; 1882-1885.
Tanboon J, Uiprasertkul M, Luemsamran P. Signet-ring cell/histiocytoid carcinoma of the eyelid: a case report and review of the literature. Am. J. Dermatopathol. 2013; 35; e1-e5.
Pryds A, Venzo A, Heegaard S, Prause JU, Toft PB. Sentinel node biopsy and frozen section procedure in signet ring cell carcinoma of the eyelid and orbit. Acta Ophthalmol. 2014; 92; 486-487.
Tan JS, McKelvie PA, Hardy TG. Primary signet ring cell carcinoma of the eyelid. Orbit 2013; 32; 399-401.
Hansen MS, Chi SL, Cummings T, Woodward JA. Uncorrectable ptosis; primary cutaneous signet-ring cell carcinoma. Dermatol. Online J. 2013; 19; 19615.
Bernárdez C, Macías del Toro E, Ramírez Bellver JL et al. Primary signet-ring cell histiocytoid carcinoma of the eyelid: a ‘binocle’ presentation of the ‘monocle tumor’. Am. J. Dermatopathol. 2016; 38; 623-627.
Sakamoto K, Ito T, Tanioka F, Fukamizu H, Tokura Y. Primary signet-ring cell/histiocytoid carcinoma of the eyelid expressing androgen receptors and treated with bicalutamide. J. Dermatol. 2017; 44; e230-e231.
Onoe A, Matsuura D, Terui T, Morikawa H, Fujii M, Ochiai T. Erythematous lesion with peripheral purpura on the face. Clin. Exp. Dermatol. 2019; 44; 428-431.
Yates JR, Mines MJ, Subramanian PS, Rivera-Michlig R, Cummings TJ, Eberhartt CG. Periocular histiocytoid carcinoma; potential diagnostic challenges. Ocul. Oncol. Pathol. 2019; 5; 94-101.
Jakobiec FA, Reshef ER, Ma L, Selig MK, Lefebvre DR, Stagner AM. Sclerosing signet ring cell carcinoma of the lacrimal gland: a potentially new primary entity. Ocul. Oncol. Pathol. 2020; 6; 265-274.
Palakkamanil MM, Mahmood MN, Chan A. Diagnostic and treatment challenges of a case of primary cutaneous signet-ring cell/histiocytoid carcinoma of the eyelid. BMC Ophthalmol. 2020; 20; 410.
Stewart S, Houghton J, Kamalarajah S, Curragh D. Primary adnexal signet-ring cell/histiocytoid carcinoma. Ophthalmic Plast. Reconstr. Surg. 2021; 37; e134-e136.
Kazakov DV, Argenyi ZB, Brenn T et al. Apocrine carcinoma. In Elder DE, Massi D, Scolyer RA, Willemze R eds. World Health Organization classification of skin tumours. Lyon: IARC Press, 2018; 174-175.
Robson A, Lazar AJF, Nagi JB et al. Primary cutaneous apocrine carcinoma: a clinico-pathologic analysis of 24 cases. Am. J. Surg. Pathol. 2008; 32; 682-690.
Kuno Y, Tsuji T, Yamamoto K. Adenocarcinoma with signet ring cells of the axilla: two case reports and review of the literature. J. Dermatol. 1999; 26; 390-395.
Zelger BG, Stelzmueller I, Dunst KM, Zelger B. Solid apocrine carcinoma of the skin: report of a rare adnexal neoplasm mimicking lobular breast carcinoma. J. Cutan. Pathol. 2008; 35; 332-336.
Kazakov DV, Michal M, Kacerovska D, McKee PH. Apocrine adenocarcinoma. In Kazakov DV, Michal M, Kacerovska D, McKee PH eds. Cutaneous adnexal tumors. Philadelphia, PA: Wilters Kluwer/Lippincott Williams & Wilkins, 2012; 85-92.
Kastnerova L, Luzar B, Goto K et al. Secretory carcinoma of the skin: report of 6 cases, including a case with a novel NFIX-PKN1 translocation. Am. J. Surg. Pathol. 2019; 43; 1092-1098.
Shin SJ, Desmedt C, Kristiansen G, Reis-Fiho JS, Sasano H. Invasive lobular carcinoma. In WHO Classification of Tumours Editorial Board ed. World Health Organization classification of tumours. Breast tumours. 5th ed. Lyon: IARC Press, 2019; 114-118.
Skotnicki P, Ryś J, Blecharz P et al. Invasive lobular carcinoma of the breast: cytometric and immunohistochemical characteristics of 96 cases. Pol. J. Pathol. 2012; 63; 112-120.
Pai RK, West RB. MOC-31 exhibits superior reactivity compared with Ber-EP4 in invasive and ductal carcinoma of the breast: a tissue microarray study. Appl. Immunohistochem. Mol. Morphol. 2009; 17; 202-206.
Polivka J Jr, Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol. Ther. 2014; 142; 164-175.
Sun X, Zuo KE, Yao Q et al. Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas. Mod. Pathol. 2020; 33; 2473-2482.
Ciriello G, Gatza ML, Beck AH et al. Comprehensive molecular portraits of invasive lobular breast cancer. Cell 2015; 163; 506-519.
Chiosea SI, Williams L, Griffith CC et al. Molecular characterization of apocrine salivary duct carcinoma. Am. J. Surg. Pathol. 2015; 39; 744-752.
Goto K, Maeda D, Kudo-Asabe Y et al. PIK3CA and AKT1 mutations in hidradenoma papilliferum. J. Clin. Pathol. 2017; 70; 424-427.